New hope for women with platinum-resistant ovarian cancer
A breakthrough treatment for women with platinum-resistant ovarian cancer has today been approved.
Topic: Cancer drugs
Draft NICE guidance does not recommend use of Elahere by NHS in England
NICE has produced draft guidance that has recommended that Mirvetuximab soravtansine (Elahere) is not used by the NHS in England
Olaparib from the second line of treatment for those with a BRCA gene variation moves into routine commissioning
Olaparib (Lynparza®) will be available long term on the NHS in England, Northern Ireland and Wales, from the second line of ovarian cancer treatment.
Future is certain for niraparib in recurrent ovarian cancer
Announcement that niraparib from second line of treatment for recurrent ovarian cancer will be available long term on the NHS in England and Wales.
Pioneering drug combination made available UK-wide
New combination of olaparib and bevacizumab means a leap forward in personalised treatments.
News on access to niraparib from second line of treatment
Initial decision announced to make niraparib available from second line of treatment only to people with a BRCA1 or BRCA2 mutation.
Breakthrough in ovarian cancer treatment with niraparib
Gamechanging drug could benefit thousands of women with advanced ovarian cancer every year.
Towards more choice: new drug rucaparib now available
New ovarian cancer drug rucaparib (Rubraca®) is now available on the NHS.
